Cameron Myhrvold

Carver Biosciences, Inc. is a gene therapy company based in Dedham, MA. Carver is developing CRISPR-based therapies for RNA viruses that infect humans, using a programmable platform technology that could offer a generalizable solution for treating many viruses. The company's underlying technology was developed by co-founder Dr. Cameron Myhrvold. Carver Biosciences is leveraging Cas13 to target respiratory viruses at the RNA level, with the aim of destroying the viruses and preventing them from replicating. The company's therapeutics would act in concert with Dr. Uri Lopatin. The company was founded by Cameron Myhrvold and Walter Strapps, with Walter Strapps serving as the CEO since incorporation.